World's Best Scientists 2026 revealed!
Cancer Immunology, Immunotherapy
H-index 43

Cancer Immunology, Immunotherapy

0340-7004

Published by: Springer

https://www.springer.com/journal/262

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Immunology 51 200 223 30
Medicine 510 332 336 34

Additional Metrics

Number of Best Scientists*: 733
Documents by Best Scientists*: 629
Top 100 Ranked Scientists*: 9
SCIMAGO H-index: 142
SCIMAGO SJR: 1.716
Impact Factor: 5.1

Overview

Top Research Topics at Cancer Immunology, Immunotherapy?

Cancer Immunology, Immunotherapy was organized to reinforce research efforts on Immunology, Immunotherapy, Cancer research, Immune system and Antigen. Topics in Immunology were tackled in line with various other fields like Cytotoxic T cell and Cancer. Cancer Immunology, Immunotherapy addresses concerns in Cytotoxic T cell which are intertwined with other disciplines, such as CD8 and Cytotoxicity.

In the journal, Melanoma, Oncology and Pathology are investigated in conjunction with one another to address concerns in Immunotherapy research. Concepts in Lymphokine-activated killer cell, as well as related topics in Natural killer cell, are covered in the Cancer research research presented in it. The work tackled in the journal goes beyond the discipline of Immune system as it also encompasses Vaccination.

The concepts on Antigen presented in Cancer Immunology, Immunotherapy can also apply to other research fields, including Molecular biology, Tumor antigen and Virology. The research on Molecular biology tackled can also make contributions to studies in the areas of Cell culture and In vitro. Topics in Internal medicine explored in the journal were investigated in conjunction with research in Gastroenterology and Endocrinology.

  • Immunology (48.61%)
  • Immunotherapy (34.84%)
  • Cancer research (31.22%)

What are the most cited papers published in the journal?

  • Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy (980 citations)
  • Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients (961 citations)
  • A listing of human tumor antigens recognized by T cells. (806 citations)

Research areas of the most cited articles at Cancer Immunology, Immunotherapy:

The most cited articles are organized to reinforce research efforts on Immunology, Immunotherapy, Immune system, Cancer research and Antigen. Issues in Immunology were discussed in the journal articles, taking into consideration concepts from other disciplines like Cytotoxic T cell and Cancer. In addition to Immunotherapy research, the journal articles aim to explore topics under Antibody, Melanoma and CD8.

What topics the last edition of the journal is best known for?

  • Cancer
  • Internal medicine
  • Gene

The previous edition focused in particular on these issues:

The journal aims to foster the development of research in Cancer research, Immunotherapy, Internal medicine, Immune system and Oncology. Cancer Immunology, Immunotherapy goes beyond the discussion of Cancer research as it connects it with closely related disciplines like

  • T cell which intersects with area such as Antigen,
  • CD8 that connect with fields like FOXP3.. While Immunotherapy is the focus of the journal, it also provided insights into the studies of Immunohistochemistry, Cell and Lung.

While Cancer Immunology, Immunotherapy focused on Immunohistochemistry, it was also able to explore topics like CD163 and Tumor-infiltrating lymphocytes. Research in the field of Immunology was used to conduct the presented Immune system study. The studies on Oncology discussed can also contribute to research in the domains of Pembrolizumab, Proportional hazards model, Hazard ratio, Biomarker (medicine) and Cohort.

The most cited articles from the last journal are:

  • ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer (15 citations)
  • Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC (13 citations)
  • Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis (12 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Cancer Immunology, Immunotherapy (based on the number of publications) are:

  • Graham Pawelec (53 papers) absent at the last edition,
  • Giorgio Parmiani (43 papers) absent at the last edition,
  • Soldano Ferrone (34 papers) absent at the last edition,
  • Constantin N. Baxevanis (34 papers) absent at the last edition,
  • Theresa L. Whiteside (32 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Cancer Immunology, Immunotherapy (based on the number of publications) are:

  • National Institutes of Health (176 papers) published 4 papers at the last edition,
  • University of Pittsburgh (121 papers) published 3 papers at the last edition the same number as at the previous edition,
  • University of Tübingen (108 papers) published 5 papers at the last edition, 3 more than at the previous edition,
  • French Institute of Health and Medical Research (103 papers) published 4 papers at the last edition the same number as at the previous edition,
  • University of Texas MD Anderson Cancer Center (98 papers) published 9 papers at the last edition, 8 more than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 4.57% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 9.82% were posted by at least one author from the top 10 institutions publishing in the journal. Another 6.05% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 21.66% of all publications and 62.47% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Top Publications

  • Chemotherapy: a double-edged sword in cancer treatment

    Nafiseh Behranvand;Farzad Nasri;Reza Zolfaghari Emameh;Pouria Khani

    (2021)
    342 Citations
  • Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients.

    Qian-Ting Wang;Ying Nie;Sheng-Nan Sun;Tao Lin

    (2020)
    103 Citations
  • Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer

    Reem Saleh;Rowaida Z. Taha;Salman M. Toor;Varun Sasidharan Nair

    (2020)
    97 Citations
  • Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients

    (2020)
    83 Citations
  • Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients.

    Daan P. Hurkmans;Merian E. Kuipers;Jasper Smit;Ronald van Marion

    (2020)
    79 Citations
  • Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.

    Yihe Yan;Yihe Yan;Leting Zheng;Leting Zheng;Qiang Du;Bing Yan

    (2020)
    77 Citations
  • Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

    Abdul Rafeh Naqash;Biagio Ricciuti;Biagio Ricciuti;Dwight H Owen;Vaia Florou;Vaia Florou

    (2020)
    76 Citations

Related Online Degrees & Career Pathways

For those interested in medicine but exploring alternative career options, pursuing degrees in health information management or nutrition can be rewarding. An online HIM degree online offers flexible access to programs that prepare students for roles in managing medical records and health data.

One popular career path within health administration is becoming a medical coder or biller. Understanding the medical coder salary helps prospective professionals gauge earning potential before committing to training. Additionally, it’s important to weigh the pros and cons, so reading about is medical billing and coding a good career can offer valuable insights.

For those passionate about nutrition and wellness, pursuing a master degree in nutrition online enables advancement in this growing field. This pathway often leads to roles in clinical nutrition, public health, or wellness coaching.

Exploring these related fields can complement a medical career or provide alternative avenues within the healthcare industry, especially through affordable and accessible online education options.

Best Scientists Contributing to This Journal